Study shows lack of testicular cancer knowledge among men

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

"I think the micronized formulation is something to think about," says Gautam Jayram, MD.

“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by December 29, 2024.

Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.